Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa

Journal of Structural Biology

Volumn 194, Issue 1, 2016, Pages 78-89

  Ahmed, Alysia A ^a,b   Keremane, Sravya R ^a   Vielmetter, Jost ^a   Bjorkman, Pamela J ^a  

^a California Institute of Technology   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Affinity; Fc receptors; Fc FcR structure; GASDALIE Fc; IgG Fc; SDALIE Fc

Indexed keywords

FC RECEPTOR; FC RECEPTOR IIIA; GASDALIE FC; IMMUNOGLOBULIN FC FRAGMENT; SDALIIE FC; UNCLASSIFIED DRUG; FCGR3A PROTEIN, HUMAN; FUCOSE; PROTEIN BINDING;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; BINDING SITE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; HYDROGEN BOND; PRIORITY JOURNAL; RECEPTOR BINDING; SURFACE PLASMON RESONANCE; AMINO ACID SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CHEMISTRY; GENETICS; GLYCOSYLATION; HEK293 CELL LINE; HUMAN; METABOLISM; MOLECULAR MODEL; MUTATION; PROTEIN DOMAIN; SEQUENCE HOMOLOGY; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; FUCOSE; GLYCOSYLATION; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; PROTEIN DOMAINS; RECEPTORS, IGG; SEQUENCE HOMOLOGY, AMINO ACID; SURFACE PLASMON RESONANCE;

EID: 84958148759     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2016.02.001     Document Type: Article

References (59)

1. Ackerman M.E., Nimmerjahn F. Antibody Fc Linking Adaptive and Innate Immunity 2014, Elsevier Science, Amsterdam; Burlington, pp. 1 online resource (xii, 363 p).
2. Adams P.D., Afonine P.V., Bunkoczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.W., Kapral G.J., Grosse-Kunstleve R.W., et al. PHENIX: a comprehensive python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:213-221.
3. Ahmed A.A., Giddens J., Pincetic A., Lomino J.V., Ravetch J.V., Wang L.X., Bjorkman P.J. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J. Mol. Biol. 2014, 426:3166-3179.
4. Anthony R.M., Ravetch J.V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 2010, 30(Suppl 1). S9-14.
5. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., Ravetch J.V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 320:373-376.
6. Anthony R.M., Wermeling F., Karlsson M.C., Ravetch J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:19571-19578.
7. Anthony R.M., Kobayashi T., Wermeling F., Ravetch J.V. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011, 475:110-113.
8. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25:21-50.
9. Bournazos S., Chow S.K., Abboud N., Casadevall A., Ravetch J.V. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J. Clin. Investig. 2014, 124:725-729.
10. Bournazos S., Klein F., Pietzsch J., Seaman M.S., Nussenzweig M.C., Ravetch J.V. Broadly neutralizing anti-HIV-antibodies require Fc effector functions for in vivo activity. Cell 2014, 158:1243-1253.
11. Bruhns P., Iannascoli B., England P., Mancardi D.A., Fernandez N., Jorieux S., Daeron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113:3716-3725.
12. Burmeister W.P., Huber A.H., Bjorkman P.J. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 1994, 372:379-383.
13. Butler M., Quelhas D., Critchley A.J., Carchon H., Hebestreit H.F., Hibbert R.G., Vilarinho L., Teles E., Matthijs G., Schollen E., et al. Detailed glycan analysis of serum glycoproteins of patients with congenital disorders of glycosylation indicates the specific defective glycan processing step and provides an insight into pathogenesis. Glycobiology 2003, 13:601-622.
14. DiLillo D.J., Ravetch J.V. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 2015, 161:1035-1045.
15. DiLillo D.J., Ravetch J.V. Fc-Receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. Cancer Immunol. Res. 2015, 3:704-713.
16. DiLillo D.J., Tan G.S., Palese P., Ravetch J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 2014, 20:143-151.
17. Diskin R., Marcovecchio P.M., Bjorkman P.J. Structure of a clade C HIV-gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat. Struct. Mol. Biol. 2010, 17:608-613.
18. Duncan A.R., Woof J.M., Partridge L.J., Burton D.R., Winter G. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 1988, 332:563-564.
19. Edberg J.C., Kimberly R.P. Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding. J. Immunol. 1997, 159:3849-3857.
20. Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of coot. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:486-501.
21. Evans P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 2006, 62:72-82.
22. Evans P.R. An introduction to data reduction: space-group determination, scaling and intensity statistics. Acta Crystallogr. D Biol. Crystallogr. 2011, 67:282-292.
23. Ferrara C., Stuart F., Sondermann P., Brunker P., Umana P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 2006, 281:5032-5036.
24. Ferrara C., Grau S., Jager C., Sondermann P., Brunker P., Waldhauer I., Hennig M., Ruf A., Rufer A.C., Stihle M., et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:12669-12674.
25. Hulett M.D., Hogarth P.M. Molecular basis of Fc receptor function. Adv. Immunol. 1994, 57:1-127.
26. Janeway C.A., Travers P., Walport M., Schlomchik M.J. Immunobiology 2005, Garland Science Publishing, New York, NY. sixth ed.
27. Kaneko Y., Nimmerjahn F., Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-673.
28. Karplus P.A., Diederichs K. Linking crystallographic model and data quality. Science 2012, 336:1030-1033.
29. Krissinel E., Henrick K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 2007, 372:774-797.
30. Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:4005-4010.
31. Leslie A.G.W., Powell H.R. Processing diffraction data with mosfilm. Evol. Methods Macromol. Crystallogr. 2007, 41-51.
32. Lin C.W., Tsai M.H., Li S.T., Tsai T.I., Chu K.C., Liu Y.C., Lai M.Y., Wu C.Y., Tseng Y.C., Shivatare S.S., et al. A common glycan structure on immunoglobulin G for enhancement of effector functions. Proc. Natl. Acad. Sci. U.S.A. 2015.
33. Matsumiya S., Yamaguchi Y., Saito J., Nagano M., Sasakawa H., Otaki S., Satoh M., Shitara K., Kato K. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 2007, 368:767-779.
34. Maxwell K.F., Powell M.S., Hulett M.D., Barton P.A., McKenzie I.F., Garrett T.P., Hogarth P.M. Crystal structure of the human leukocyte Fc receptor, Fc gammaRIIa. Nat. Struct. Biol. 1999, 6:437-442.
35. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40:658-674.
36. Mimoto F., Katada H., Kadono S., Igawa T., Kuramochi T., Muraoka M., Wada Y., Haraya K., Miyazaki T., Hattori K. Engineered antibody Fc variant with selectively enhanced FcgammaRIIb binding over both FcgammaRIIa (R131) and FcgammaRIIa (H131). Protein Eng. Des. Select.: PEDS 2013, 26:589-598.
37. Mizushima T., Yagi H., Takemoto E., Shibata-Koyama M., Isoda Y., Iida S., Masuda K., Satoh M., Kato K. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells: Mol. Cell. Mech. 2011, 16:1071-1080.
38. Nieba L., Krebber A., Pluckthun A. Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics. Anal. Biochem. 1996, 234:155-165.
39. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 2008, 26:513-533.
40. Oganesyan V., Damschroder M.M., Leach W., Wu H., Dall'Acqua W.F. Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol. Immunol. 2008, 45:1872-1882.
41. Oganesyan V., Gao C., Shirinian L., Wu H., Dall'Acqua W.F. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr. D Biol. Crystallogr. 2008, 64:700-704.
42. Okazaki A., Shoji-Hosaka E., Nakamura K., Wakitani M., Uchida K., Kakita S., Tsumoto K., Kumagai I., Shitara K. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J. Mol. Biol. 2004, 336:1239-1249.
43. Radaev S., Motyka S., Fridman W.H., Sautes-Fridman C., Sun P.D. The structure of a human type III Fcgamma receptor in complex with Fc. J. Biol. Chem. 2001, 276:16469-16477.
44. Ramsland P.A., Farrugia W., Bradford T.M., Sardjono C.T., Esparon S., Trist H.M., Powell M.S., Tan P.S., Cendron A.C., Wines B.D., et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J. Immunol. 2011, 187:3208-3217.
45. Ravetch J.V., Bolland S. IgG Fc receptors. Annu. Rev. Immunol. 2001, 19:275-290.
46. Ravetch J.V., Kinet J.P. Fc receptors. Annu. Rev. Immunol. 1991, 9:457-492.
47. Richards J.O., Karki S., Lazar G.A., Chen H., Dang W., Desjarlais J.R. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 2008, 7:2517-2527.
48. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
49. Sazinsky S.L., Ott R.G., Silver N.W., Tidor B., Ravetch J.V., Wittrup K.D. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:20167-20172.
50. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T.Y., Pietzsch J., Fenyo D., Abadir A., Velinzon K., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637.
51. Schrödinger, L., 2011. The PyMOL Molecular Graphics System (The PyMOL Molecular Graphics System).
52. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 2001, 276:6591-6604.
53. Smith P., DiLillo D.J., Bournazos S., Li F., Ravetch J.V. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:6181-6186.
54. Sondermann P., Huber R., Jacob U. Crystal structure of the soluble form of the human fcgamma-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution. EMBO J. 1999, 18:1095-1103.
55. Sondermann P., Huber R., Oosthuizen V., Jacob U. The 3.2-crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000, 406:267-273.
56. Sondermann P., Kaiser J., Jacob U. Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J. Mol. Biol. 2001, 309:737-749.
57. Sondermann P., Pincetic A., Maamary J., Lammens K., Ravetch J.V. General mechanism for modulating immunoglobulin effector function. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:9868-9872.
58. Sprague E.R., Martin W.L., Bjorkman P.J. PH dependence and stoichiometry of binding to the Fc region of IgG by the herpes simplex virus Fc receptor gE-gI. J. Biol. Chem. 2004, 279:14184-14193.
59. 3 interface. Mol. Immunol. 2013, 56:131-139.